Related Experiment Videos
[Hepatitis C--standard therapy].
1Abteilung für Gastroenterologie, Hepatologie und Endokrinolologie, Medizinische Universitätsklinik Freiburg. rasenack@mm21.ukl.uni-freiburg.de
Praxis
|July 21, 2000
Summary
Hepatitis C virus (HCV) infection often causes chronic hepatitis. Antiviral treatments like interferon-alpha and ribavirin offer a 40% sustained response rate, improving liver health and reducing cancer risk.
Area of Science:
- Hepatology
- Virology
- Immunology
Context:
- Hepatitis C virus (HCV) infection frequently leads to chronic hepatitis, with cirrhosis developing in a minority over two decades.
- HCV-induced cirrhosis is more common than that from hepatitis B infection.
Purpose:
- To review the diagnosis, natural course, and treatment of hepatitis C virus infection.
- To evaluate the efficacy and impact of interferon-alpha-based therapies on liver disease progression and outcomes.
Summary:
- Diagnosis involves anti-HCV antibodies and HCV RNA detection. Standard treatment combines interferon-alpha with ribavirin, achieving a 40% sustained virologic response rate.
- Treatment improves liver histology, reducing necroinflammation and fibrosis. Interferon-alpha also lowers hepatocellular carcinoma rates and delays decompensation in Child A cirrhosis patients.
- Treatment decisions should be individualized, considering patient factors like age, comorbidities, and liver disease stage due to slow progression, modest response rates, and potential adverse events.
Impact:
- Interferon-alpha and ribavirin therapy can halt or slow liver disease progression, reducing long-term complications.
- Improved histological outcomes and reduced cancer incidence contribute to better patient prognosis and quality of life.
- Personalized treatment strategies enhance therapeutic benefits while managing risks associated with antiviral therapy for chronic hepatitis C.